Skip to main content
. Author manuscript; available in PMC: 2019 Jun 19.
Published in final edited form as: Nat Genet. 2016 Sep 19;48(11):1330–1338. doi: 10.1038/ng.3670

Figure 5. Overall survival of TCGA bladder cancer patients is improved with increased APOBEC mutagenesis and in carriers of bladder cancer risk genotype rs17000526-AA.

Figure 5.

(A and B). APOBEC-signature mutations and APOBEC mutagenesis pattern were divided into quartiles (I - lowest and IV - highest mutation loads) and plotted against months of overall survival (OS). Multivariate Cox regression models were used to calculate hazards ratios (HR) with 95% confidence intervals (CI) and p-values for quartiles II, III, or IV vs. I (reference) as well as III and IV vs I and II. (C). Hazards ratios for SNP rs17000526 were calculated by comparing the AA or AG vs. GG genotype (reference) or AA vs. AG and GG genotypes (reference). Multivariate models included age, gender, and tumor stage. Data used for this analysis is presented in Supplementary Data Set 1.